Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 2 diabetes mellitus. Sold as Micronase, Diabeta, Glynase, Glyburide. Every FDA application for this active ingredient: 4 branded and 15 generic.
As of Nov 14, 2026, FDA lists 19 applications for Glyburide (sold as Micronase, Diabeta, Glynase and others), first approved May 1, 1984, with 0 new uses approved and 0 published complete response letters.
First approved: May 1, 1984
Applications: 19
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $2.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Glyburide
Part D
$2.9M
-4%
51,966
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
GLYBURIDE 1.25 MG TABLET: $0.060 per unitGeneric · -31% in a year
GLYBURIDE 2.5 MG TABLET: $0.065 per unitGeneric · -23% in a year
GLYBURIDE 5 MG TABLET: $0.068 per unitGeneric · +9% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Pfizer
Sanofi Aventis US
Teva
Strides Pharma Intl
Hikma
Aurobindo Pharma
Impax Labs Inc
Zydus Pharms